Eflornithine

DEA Class; Rx

Common Brand Names; Ornidyl, Vaniqa

  • Antiprotozoal Agents
  • Topical Skin Products

Antiprotozoal agent
Used topically to reduce unwanted facial hair in women and parenterally to treat African trypanosomiasis (sleeping sickness)
In US only available as topical cream; IV only available from the WHO/CDC

Indicated for the reduction of unwanted facial hair in females, including hirsutism of the face.
For the treatment of African trypanosomiasis (sleeping sickness) due to Trypanosoma brucei gambiense with CNS involvement.

Hypersensitivity to eflornithine or any ingredient in the formulation

  • Anemia (55%)
  • Leukopenia (37%)
  • Thrombocytopenia (14%)
  • Seizures (may be due to the disease) (8%)
  • Dizziness
  • Alopecia
  • Vomiting, diarrhea
  • Eosinophilia
  • Hearing impairment

Only available from WHO; supply very limited

Discontinue if sensitivity occurs

Pregnancy Category: C

Lactation: excretion in milk unknown; use with caution

Adults

400 mg/kg/day IV.

Elderly

400 mg/kg/day IV.

Adolescents

500 mg/kg/day IV.

Children

500 mg/kg/day IV.

Eflornithine hydrochloride

injectable solution

  • 200mg/mL

cream

  • 13.9%

About the Author

You may also like these

0